Ipilimumab Retreatment
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Ipilimumab Retreatment

› Forums › General Melanoma Community › Ipilimumab Retreatment

  • This topic is empty.
  • Post
    • March 28, 2014 at 1:10 pm
    lou2
    Participant

    Ipilimumab Retreatment in Patients With Pretreated Advanced Melanoma

     

    Research · March 11, 2014
     

    TAKE-HOME MESSAGE

    • In this retrospective analysis of patients previously treated with ipilimumab and noted to have progression on imaging, retreatment with ipilimumab resulted in disease control in 55% of patients, with 42% still alive at 2 years and a median overall survival of 21 months. 
    • Although only a small number of patients were included, this analysis demonstrates that ipilimumab retreatment is possible and can provide continued disease control in a subset of patients with a minimal increase in toxicity.  

    – Chris Tully, MD

     

    ABSTRACT

    Background

    Retreatment with ipilimumab has been shown to re-establish disease control in some patients with disease progression. Here, we report the efficacy and safety of retreatment with ipilimumab 3 mg kg−1 among patients participating in an expanded access programme in Italy.

    Methods

    Patients who achieved disease control during induction therapy were retreated with ipilimumab upon progression (3 mg kg−1 every 3 weeks for up to four doses), providing they had not experienced toxicity that precluded further dosing. Tumour assessments were conducted after retreatment, and patients were monitored throughout for adverse events.

    Results

    Of 855 patients treated with ipilimumab, 51 were retreated upon disease progression. Of these, 28 (55%) regained disease control upon retreatment and 42% were alive 2 years after the first induction dose of ipilimumab; median overall survival was 21 months. Eleven patients (22%) had a treatment-related adverse event of any grade during retreatment. These were generally mild-to-moderate and resolved within a median of 4 days. No new types of toxicity were reported.

    Conclusions

    For patients who meet predefined criteria, retreatment with ipilimumab is generally well tolerated and can translate into clinical benefit. This strategy should be compared with other therapeutic options in randomised controlled trials.

    British Journal of Cancer

    Ipilimumab Retreatment in Patients With Pretreated Advanced Melanoma: The Expanded Access Programme in Italy

    Br. J. Cancer 2014 Mar 11;[EPub Ahead of Print], V Chiarion-Sileni

     

  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics